Navigation Links
Breast-Specific Gamma Imaging (BSGI) Can Reduce the Number of Unnecessary Breast Biopsies When Compared to MRI

Pivotal Study Presented at Interdisciplinary Breast Center Conference

NEWPORT NEWS, Va., March 18 /PRNewswire/ -- Women that require additional diagnostic imaging after a questionable mammogram may be at risk for unnecessary biopsies when only magnetic resonance imaging (MRI) is offered, according to a new study presented at the 19th Annual National Interdisciplinary Breast Center Conference in Las Vegas.

"Our goal was to see if BSGI could be used to improve upon the specificity of MRI, and also reduce the number of biopsies. The study is important because with the addition of BSGI, we could eliminate the need for 50 percent of biopsies or possibly change a patient's decision to have more radical surgery," said Dr. Leora Lanzkowsky, Director of Women's Imaging, CHW - Nevada Imaging Centers in Las Vegas.

BSGI has comparable sensitivity but superior specificity when compared to MRI. Sensitivity refers to the ability of an imaging technique to detect the presence of disease. Specificity refers to the technique's ability to detect that disease is actually not present.

BSGI, a molecular breast imaging technique, is a follow-up to mammography that can see lesions independent of tissue density and discover early stage cancers. With BSGI, the patient receives a pharmaceutical tracing agent that is absorbed by all the cells in the body. Due to their increased rate of metabolic activity, cancerous cells in the breast absorb a greater amount of the tracing agent than normal, healthy cells and generally appear as "hot spots" on the BSGI image. The Dilon 6800 Gamma Camera is a high-resolution, compact gamma camera, optimized to perform BSGI. The camera provides a manageable four to 16 images versus up to thousands of images with breast MRI.

The Study

Over the course of 18 months, at three medical centers, BSGI and MRI were performed in women requiring additional diagnostic imaging following a mammogram as deemed necessary by a physician. The majority of these patients had either a personal history of breast cancer or a combination of other factors placing them at high-risk for breast carcinoma. The interpreting radiologist had access to all prior images and patient information for image interpretation for both studies. All biopsies were performed as deemed necessary by a physician.

Sensitivity Results

There were 120 women who had 122 abnormal biopsies requiring additional intervention. There were a total of 16 high-risk lesions (11 ADH, four LCIS and one papilloma) and 106 malignant lesions (17 DCIS, 70 IDC, 14 ILC, three papillary carcinomas, one tubular and one squamous cell carcinoma). BSGI was negative in a total of 10 cases (six malignancies and four high risk lesions) and indeterminate in three (all malignancies). MRI was negative in a total of 11 cases (seven malignancies and four high risk lesions) and indeterminate in six (three malignancies and three high-risk lesions). Excluding the indeterminate findings from the sensitivity analysis, BSGI was positive 110/120 cases (90.6 percent sensitivity) and MRI was positive in 106 out of 117 cases (90.6 percent sensitivity). BSGI was equal in sensitivity to breast MRI in the detection of malignant and high-risk breast lesions, while reducing the rate of indeterminate findings by 50 percent.

Specificity Results

Of the 37 patients who had benign biopsy results, MRI and BSGI were concordant in 16 patients yielding a specificity of 38 percent. For the patients with discordant MRI and BSGI findings, BSGI specificity was 52 percent while MRI had a specificity of 19 percent. Overall, the specificity for BSGI and MRI were 46 percent and 27 percent respectively.

"If we can utilize BSGI to avoid unnecessary biopsies, not only are we saving women from an uncomfortable procedure, scarring and the expense of surgery, we save time so patients can move more quickly to treatment," said Dr. Lanzkowsky. She went on to say, "In this group of patients with complex radiographic findings requiring both BSGI and MRI in the course of clinical care, BSGI provided comparable sensitivity, higher specificity and fewer indeterminate results than MRI."

About Dilon Technologies

Dilon Technologies Inc. is bringing innovative new medical imaging products to market. Dilon's cornerstone product, the Dilon 6800, is a high-resolution, compact gamma camera, optimized to perform BSGI, a molecular breast imaging procedure which images the metabolic activity of breast lesions through radiotracer uptake. Many leading medical centers around the country are now offering BSGI to their patients, including: Cornell University Medical Center, New York; George Washington University Medical Center, Washington, D.C.; and The Rose, Houston. For more information on Dilon Technologies please visit

SOURCE Dilon Technologies Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Breast-Specific Gamma Imaging (BSGI) Uncovers Additional Breast Cancer in Newly Diagnosed Breast Cancer Patients
2. Dilon Technologies Signs Amerinet for Breast-Specific Gamma Imaging
3. Breast-Specific Gamma Imaging (BSGI) Found to Be Highly Sensitive for Early Stage Breast Cancer
4. Breast Cancer Imaging Study Indicates Breast-Specific Gamma Imaging (BSGI) Is a Strong Adjunct Imaging Modality to Mammography and Ultrasound
5. Breast-Specific Gamma Imaging (BSGI) Changes Patient Care Management
6. Study Determines Breast-Specific Gamma Imaging Has Higher Specificity Than MRI in Patients With Equivocal Mammograms
7. Gamma Pharmaceuticals Accepts PO From Leading St. Louis Missouri Distributor. Order Valued up to $850,000 Retail Market Value
8. Number of cardiovascular risk factors could determine safety of intravenous gammaglobulin treatment
9. M. D. Anderson Cancer Center Acquires Leksell Gamma Knife Perfexion for Targeted Brain Lesion Treatments
10. ETEX Corporation Announces CE Mark of Beta-bsm and Gamma-bsm
11. What is the suppressing effect of the PPAR-gamma ligands on stomach cancer cells?
Post Your Comments:
(Date:10/12/2015)... ... 2015 , ... The American Society of Clinical Hypnosis (ASCH) ... and clinical training in a health care discipline. , Many practitioners claim ... losing weight, managing pain, or stopping smoking, etc. Frequently, extravagant statements and guarantees ...
(Date:10/12/2015)... ... October 12, 2015 , ... AcousticSheep LLC, creators of ... in honor of Breast Cancer Awareness Month. During the month of October, ... a SleepPhones® Classic product to a breast cancer patient at the Cleveland Clinic. ...
(Date:10/12/2015)... ... October 12, 2015 , ... To help ... its charitable donation to the National Breast Cancer Foundation. The National Breast Cancer ... breast cancer through early detection, education, and support services. , The annual campaign ...
(Date:10/12/2015)... ... October 12, 2015 , ... NFL football fans who are interested in having an opportunity to ... CLICK HERE to donate to Smile for a Lifetime (S4L) Foundation and gift ... all-inclusive trip to the 2016 NFL Super Bowl! , Donors contributing $20.00 or more between ...
(Date:10/12/2015)... , ... October 12, 2015 , ... The translation for ... seamless migration of complete ARIS installations into the Microsoft world. The ARIS models ... As Microsoft Visio® is very familiar for both IT and Office users it is ...
Breaking Medicine News(10 mins):
(Date:10/12/2015)... October 12, 2015 ... to grow at 7.2% CAGR, microscopy market ... rising focus on nanotechnology, technological advancements, and ... report available with ... . --> Complete report on ...
(Date:10/12/2015)...   Royal Philips (NYSE: PHG, AEX: PHIA), ... a collaboration with Genomic Health , Inc. (NASDAQ: ... diagnostic tests, to leverage Philips digital pathology tools in ... testing processes.    --> ... samples and plays a crucial role in the diagnosis ...
(Date:10/12/2015)... , Oct. 12, 2015 Indivior PLC (LON: ... District of Delaware granted the Company,s ... Pharmaceuticals, Abbreviated New Drug Application (ANDA) No. 205299 to market ... (buprenorphine and naloxone) Sublingual Film (CIII) in the ... --> Since August 2013, Indivior has received Paragraph IV ...
Breaking Medicine Technology: